Ocugen, Inc. will present at upcoming Citi and HC

MALVERN, Pa., September 7, 2021 (GLOBE NEWSWIRE) – Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on the discovery, development and commercialization of gene therapies to cure diseases of blindness and develop a vaccine to fight COVID -19, today announced its participation in Citi’s 16th Annual BioPharma Virtual Conference to be held September 8-10, 2021 and HC Wainwright Global Investment Conference to be held from September 13 until September 15, 2021.

Dr. Shankar Musunuri, CEO and Co-Founder, will give a virtual presentation at the Citi conference and Sanjay Subramanian, CFO and Head of Corporate Development, will make a virtual presentation to HC Wainwright. The two will provide updates on COVAXIN â„¢, the investigational COVID-19 vaccine that the company is jointly developing with Bharat Biotech for the US and Canadian markets. They will also present information on Ocugen’s revolutionary gene modifier therapy platform, which has generated product candidates expected to enter Phase 1 / 2a clinical trials in ophthalmic disease states over the next 18 months.

Cat by the fireside Citi / Ocugen
Date hour : Wednesday, September 8, 2021, 3:15 p.m. – 4:00 p.m. EST
Registration link: https://kvgo.com/citi-16th-annual-biopharma-vc/ocugen-inc-sept-2021

HC Wainwright Global Investment Conference
Date hour : Presentation available upon request starting at 7:00 a.m. Eastern Time on September 13, 2021
Registration link: https://journey.ct.events/view/705764c5-88a7-4a4c-afff-d1688de5a5d9

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of gene therapies to cure diseases of blindness and the development of a vaccine to save lives against COVID-19. Our revolutionary modifying gene therapy platform has the potential to treat multiple retinal diseases with a single drug – “one for many”, and our new biologic product candidate aims to provide better therapy for patients with underserved conditions such as macular degeneration. wet age-related, diabetics. macular edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN â„¢ vaccine candidate against COVID-19 in the US and Canadian markets. For more information, please visit www.ocugen.com.

Caution regarding forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predict”, “believe”, “potential”, “propose”, “continue”, “estimate”, “anticipate”, “expect”, “foresee” , “Intends,” “may”, “could”, “could”, “will”, “should” or other words that convey the uncertainty of future events or results to identify such forward-looking statements. These statements are subject to many important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as risks and uncertainties regarding the market and other conditions and timing. of our planned clinical trials. These and other risks and uncertainties are described in more detail in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the second. All forward-looking statements we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, after the date of this press release. Press release.

Ocugen contact:
Ken Inchausti
Manager, Investor Relations and Communications
[email protected]

Previous "Unfair dismissal" of worker who posted YouTube video with "n word" in office chat
Next Cam Newton clarifies his release from the New England Patriots

No Comment

Leave a reply

Your email address will not be published.